Announcements Trials
Browse Landscape

Status

Approved for marketing 2Available 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 411Observational 26Expanded_access 3

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1Genitourinary 1

Conditions

Gastrointestinal Neoplasms 2Gastrointestinal Stromal Tumors 1Carcinoma, Renal Cell 1

Interventions

3-Iodobenzylguanidine 9Amifampridine 6nilotinib 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5trametinib 4pembrolizumab 4gallium 68 PSMA-11 4fludarabine 4elotuzumab 4dabrafenib 4Nivolumab 4Bortezomib 4Afatinib 4venetoclax 3regorafenib 3midostaurin 3fludarabine phosphate 3TIC10 compound 3Sunitinib 3Prednisone 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Crizotinib 3Capecitabine 3Axitinib 3Alpelisib 3Abiraterone Acetate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Expanded_access × Sunitinib × Clear all
NCT06948955 2026-05-08

Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors

Cogent Biosciences, Inc.

Available
GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

NCT00094029 2012-03-09

A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248

Pfizer

Approved for marketing
Gastrointestinal

Gastrointestinal Neoplasms

NCT00130897 2012-03-09

Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

Pfizer

Approved for marketing
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡